anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A 21-year-old gentleman presented with low responsiveness and an unwitnessed tonic-clonic seizure. A 3-day history of fevers, headaches, and poor sleep was reported. He was initially treated for meningoencephalitis. Subsequently, he developed an erythematous rash over the face and chest. He had three generalised tonic-clonic seizures and his Glasgow Coma Score (GCS) deteriorated to 8 out of 15 requiring intubation and ventilation, and antiepileptics. Lumbar puncture (LP) results were unremarkable; however, the computed tomography (CT) head concluded bilateral haemorrhages and commented on the possibility of cerebral venous sinus thrombosis (CVST). Computed tomography venogram (CTV) confirmed CVST in the superior sagittal sinus, cortical vein and left transverse sinus. Repeat CT head revealed no new changes. Clinically, he exhibited residual left-sided weakness following stroke secondary to CVST. The patient was discharged with lifelong warfarin due to unprovoked CVST. He re-presented ten months later with persistent headaches. Clinical review noted bilateral papilloedema and he required LP to relieve raised intracranial pressure (ICP). In a 5-year follow-up, he continues to have raised ICP and associated headaches requiring further LPs. He continues to take warfarin, levetiracetam and topiramate, for headaches. This is an atypical case of CVST presenting initially with meningoencephalitis-like symptoms, demonstrating diverse clinical presentation. Ergo, this encourages an early multidisciplinary approach in presentations of headaches and seizures as clinical suspicion for CVST is high. Ultimately, this will appropriately identify patients for neuroimaging with computed tomography/magnetic resonance venogram. Furthermore, 5-year follow-up is presented in this case highlighting the importance of long-term follow-up in view of variable long-term complications that remain difficult to predict.
Patients eligible for this study will be receiving OCREVUS as part of their routine care for MS treatment, and undergo the standard monitoring tests and procedures for MS patients receiving treatment. In addition, they will complete the EDSS scale on 6 occasions over a 12-month period, and the MSIS-29 on three occasions during the 12 month period for research.
The present invention relates to a pharmaceutical composition, a food composition and a food additive for preventing or alleviating symptoms of andropause, all of which contain an extract of Ficus auriculata Lour. as an active ingredient. An extract of Ficus auriculata Lour. of the present invention inhibits the activity of PDE5 so as to exhibit effects of preventing and alleviating erectile dysfunction and inhibits the expression of AR and PSA so as to exhibit effects of preventing and alleviating prostatic hyperplasia. Therefore, an extract of Ficus auriculata Lour. of the present invention can be effectively used as an active ingredient of a pharmaceutical composition, a food composition, and a food additive for alleviating andropause syndrome/symptoms.
Hydromorphone Hydrochloride Injection is an opioid agonist and available as an aqueous sterile solution, for use for intravenous, intramuscular and subcutaneous administration. It contains hydromorphone as active pharmaceutical ‎ingredient in the form of hydrochloride salt. ‎The chemical name of hydromorphone hydrochloride is 4,5α- epoxy-3-hydroxy-17-methylmorphinan-6-one hydrochloride. The molecular weight is 321.8 and it has the following chemical structure.

Hydromorphone hydrochloride is a white or almost white crystalline powder that is freely soluble in water, very slightly soluble in ethanol (96%), and practically insoluble in methylene chloride.

Each mL of Hydromorphone Hydrochloride Injection sterile solution contains 1 mg, 2 mg, or 4 mg of ‎Hydromorphone Hydrochloride USP, equivalent to 0.89 mg, 1.77 mg or 3.55 mg of hydromorphone ‎free base, respectively, 0.24 mg of Lactic Acid USP, 5.40 mg of Sodium Chloride as isotonicity agent, 8.93 ‎mg of Sodium Lactate USP as buffering agent, and Lactic Acid USP and Sodium Hydroxide NF as pH ‎adjusters, in Water for Injection. Hydromorphone Hydrochloride Injection pH range is 3.5 to 5.5. ‎
Provided in the present invention are a pharmaceutical composition for treating sepsis, and the use thereof, which belong to the technical field of chemical drugs. Provided in the present invention is a pharmaceutical composition containing three components of Hydroxysafflor yellow A, Paeoniflorin and Albiflorin. Further provided is a pharmaceutical composition containing seven components of Hydroxysafflor yellow A, Paeoniflorin, Albiflorin, Oxypaeoniflorin, Senkyunolide I, salvianic acid A sodium and ferulic acid. The present invention verifies at cell level and animal level that the two pharmaceutical compositions have the efficacy of effectively treating sepsis. In addition, a drug toxicity experiment shows that the drug has a relatively high safety. The pharmaceutical composition provided in the present invention is a medicinal ingredient of Xuebijing injection, and can be used for the clinical treatment of sepsis.
The invention belongs to the field of biological medicine, and discloses a human serum albumin adhesion peptide and application thereof. The amino acid sequence of the human serum albumin adhesion peptide provided by the invention is selected from at least one of the sequences shown in SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 or SEQ ID NO. 4. The present invention also provides a nucleotide sequence encoding the amino acid sequence of a human serum albumin adhesion peptide as described above. The human serum albumin adhesion peptide provided by the invention has higher HSA adhesion, and the adhesion peptide serving as a carrier can improve the in vivo half-life of a target protein.
The diagnostic tests Ang II, Ang-(1-7), FGF23, and klotho will be measured in the cohort. Patients in the cohort will have the diseases X-linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets type 1 (ARHR1), autosomal recessive hypophosphatemic rickets type 2 (ARHR2), osteoglophonic dysplasia, Jansen-type metaphyseal chondrodysplasia, Raine syndrome, McCune-Alright syndrome, and epidermal nevus syndrome (ENS).
The present invention relates to an oil-type cosmetic composition which has a thick slip sense and excellent moisture evaporation barrier properties, and can be easily used. The oil-type cosmetic composition is made of a composition having very excellent moisture evaporation barrier properties according to a skin constitution of a baby. Meanwhile, conventional products use mineral oil having high flowability. Accordingly, when a parent applies the oil to a baby by using his/her hand, the oil flows and thus the parent feels inconvenient. To this end, ease in using a formulation is improved by using an oil gelling agent in the present invention. In addition, due to a thick slip sense, a parent can be satisfied by feeling that a formulation is thickly and sufficiently applied to a baby, and gloss makes the skin of the baby look moist after the application of the formulation.
The reinforcing value of food varies greatly among individuals, but is strongest for those who are overweight or obese. Reducing energy intake, which is necessary for overweight and obese individuals to achieve a healthier body weight, increases the reinforcing value of food - especially for energy-dense snack foods. Food is a powerful reinforcer and is associated with energy intake; making it a primary contributing factor to an individual's weight loss struggle. Developing a way to decrease or limit the increase in food reinforcement during energy deficits would have important clinical impact. High-protein diets are known to be efficacious for weight loss and recently have been shown to decrease stimulation of the reward areas of the brain that stimulate reward-driven eating behavior. Nonetheless, sustaining a high-protein diet can be difficult, especially for women. Consuming a modest amount of protein at each meal may be better tolerated. However, we do not know whether this pattern of protein intake can assist women in staying "on track" with weight loss goals. This study will help begin to elucidate the connections between the daily pattern of protein intake on diet adherence, alterations in food reinforcement, and favorable body composition changes during weight loss.
LID015385 contact lenses worn at least 5 days per week and 8 hours per day in a daily wear modality (that is, not worn while sleeping) for approximately 3 months. CLEAR CARE will be used for nightly cleaning and disinfection.
Each participant produces a list of speech tasks that include syllables, phrases, reading passages, and open-ended questions using the MyoVoice system. Myovoice pitch and loudness recognition accuracy of speech is evaluated. Duration: 30 mins to 2 hours.
A protein which as an active protein has (a) a mol. wt. of 18000 +/- 3000 D, (b) an isoelectric point of pH 4.5-5.2, the protein being purified via a Superose 12 HR column and a CH-activated Sepharose column including coupled thrombin and being applied to a gel for isoelectric focusing in the range of pH 3-9 and (c) the N-terminal sequence of Ala-Glu-Gly-Asp-Asp-Cys-Ser-Leu-Glu-Lys-Ala-Met-Gly-Asp-Phe. Also claimed is (i) a cDNA or DNA encoding a thrombin inhibitor with features (a)-(c) above or modifications thereof with one or two amino acid substitutions, insertions or deletions without impairing its function, (ii) a vector encoding the DNA of (i), (iii) a host cell transformed with the vector of (ii), and (iv) methods for the prodn. and purificn. of the protein. The protein is found in the saliva of Triatoma pallidipennis (Tpal.) from where it can be isolated. USE - The protein is used as pharmaceutically effective agent (claimed), i.e. as a thrombin inhibitor. It can be used in a medicament for the treatment of thrombosis, instable angina or arteriosclerosis.
The present invention provides a composition used for thermotherapy. The composition includes a carrier structure and a plurality of metal particles. The carrier structure includes a lipid layer, a positive charged polymer and a surface active polymer. The positive charged polymer and the surface active polymer are respectively dispersed on the lipid layer by non-covalent bonding. The metal particles are encapsuled in the carrier structure. The present invention also provides a producing method of the composition used for thermotherapy and a use of cancer treatment of the composition.
Control group (n=200) - will consist of 100 AAA males / 100 AAA females randomly selected participants. This group will receive the standard of care by launching a mobile app that will play a dating sim game (called Choices). They will also receive pamphlets that provide information on the testing location and care if they have HIV/STI.
Dabigatran etexilate capsules should be swallowed whole. Dabigatran etexilate capsules should be taken with a full glass of water. Breaking, chewing, or emptying the contents of the capsule can result in increased exposure [see Clinical Pharmacology (12.3)].

If a dose of dabigatran etexilate capsules is not taken at the scheduled time, the dose should be taken as soon as possible on the same day; the missed dose should be skipped if it cannot be taken at least 6 hours before the next scheduled dose. The dose of dabigatran etexilate capsules should not be doubled to make up for a missed dose.

Consider administration with food if gastrointestinal distress occurs with dabigatran etexilate capsules.
BACKGROUND: Life-long immunosuppressive therapy after lung transplantation (LT) may lead to end-stage renal disease (ESRD), requiring renal replacement therapy (RRT). We aimed to investigate the characteristics and long-term outcomes of patients undergoing LT and requiring RRT.
METHODS: This study was a single-center, retrospective cohort study. The patients were divided into the RRT (n = 15) and non-RRT (n = 170) groups. We summarized the clinical features of patients in the RRT group and compared patient characteristics, overall survival, and chronic lung allograft dysfunction (CLAD)-free survival between the two groups.
RESULTS: The cumulative incidences of ESRD requiring RRT after LT at 5, 10, and 15 years were 0.8 %, 7.6 %, and 25.2 %, respectively. In the RRT group, all 15 patients underwent hemodialysis but not peritoneal dialysis, and two patients underwent living-donor kidney transplantation. The median follow-up period was longer in the RRT group than in the non-RRT group (P < 0.001). The CLAD-free survival and overall survival did not differ between the two groups. The 5-year survival rate even after the initiation of hemodialysis was 53.3 %, and the leading cause of death in the RRT group was infection.
CONCLUSIONS: Favorable long-term outcomes can be achieved by RRT for ESRD after LT.
The VALsartan In Acute myocardial iNfarcTion trial (VALIANT) was a randomized, controlled, multinational, double-blind study in 14,703 patients with acute myocardial infarction and either heart failure (signs, symptoms or radiological evidence) or left ventricular systolic dysfunction (ejection fraction ≤40% by radionuclide ventriculography or ≤35% by echocardiography or ventricular contrast angiography). Patients were randomized within 12 hours to 10 days after the onset of myocardial infarction symptoms to one of three treatment groups: valsartan (titrated from 20 or 40 mg twice daily to the highest tolerated dose up to a maximum of 160 mg twice daily), the ACE inhibitor, captopril (titrated from 6.25 mg three times daily to the highest tolerated dose up to a maximum of 50 mg three times daily), or the combination of valsartan plus captopril. In the combination group, the dose of valsartan was titrated from 20 mg twice daily to the highest tolerated dose up to a maximum of 80 mg twice daily; the dose of captopril was the same as for monotherapy. The population studied was 69% male, 94% Caucasian, and 53% were 65 years of age or older. Baseline therapy included aspirin (91%), beta-blockers (70%), ACE inhibitors (40%), thrombolytics (35%) and statins (34%). The mean treatment duration was 2 years. The mean daily dose of Valsartan in the monotherapy group was 217 mg.  
The primary endpoint was time to all-cause mortality. Secondary endpoints included (1) time to cardiovascular (CV) mortality, and (2) time to the first event of cardiovascular mortality, reinfarction, or hospitalization for heart failure. The results are summarized in the following table.

  
  
  


There was no difference in overall mortality among the three treatment groups. There was thus no evidence that combining the ACE inhibitor captopril and the angiotensin II blocker valsartan was of value.   
The data were assessed to see whether the effectiveness of valsartan could be demonstrated by showing in a non-inferiority analysis that it preserved a fraction of the effect of captopril, a drug with a demonstrated survival effect in this setting. A conservative estimate of the effect of captopril (based on a pooled analysis of 3 post-infarction studies of captopril and 2 other ACE inhibitors) was a 14% to 16% reduction in mortality compared to placebo. Valsartan would be considered effective if it preserved a meaningful fraction of that effect and unequivocally preserved some of that effect. As shown in the table, the upper bound of the CI for the hazard ratio (valsartan/captopril) for overall or CV mortality is 1.09 to 1.11, a difference of about 9% to 11%, thus making it unlikely that valsartan has less than about half of the estimated effect of captopril and clearly demonstrating an effect of valsartan. The other secondary endpoints were consistent with this conclusion.  
Effects on Mortality Amongst Subgroups in VALIANT  
  
There were no clear differences in all-cause mortality based on age, gender, race, or baseline therapies, as shown in the figure above.
The invention provides a polycaprolactone-polyphosphoester block copolymer, a liquid composition composed of the block copolymer, a nucleic acid preparation, preparation methods of the block copolymer and the liquid composition, and applications thereof in a nucleic acid medicine delivery system. According to the invention, the obtained block copolymer has good biocompatibility, low cell toxicity, and degradability. Micelles provided by the invention are subjected to self-assembly in the water solution, such that nano-particles are formed. The nano-particles have good stability, good biocompatibility, low cell toxicity, and degradability. The preparation methods are simple, and have high repeatability. As a carrier, the liquid composition can protect small nucleic acids such as siRNA against degradation. With the scale effect of the nano-particles, the material can be used in treating different diseases. Also, by bonding targeting groups, specific identification of different cancer cells can be realized.
The invention relates to a computer-aided diagnosis method for liver tumor CT images. The method segments the liver and the tumor through a Full Convolution Network (FCN), and classifies the liver tumor through a Convolution Neural Network (CNN). In training the FCN model, a weighted cross-entropy loss function is used to improve the accuracy of tumor segmentation. In training and classification using CNN, a 1-channel CT image and a 3-channel FCN segmentation result are stitched into 4-channel image data as their inputs. And finally, combining the trained FCN and CNN models to construct a computer-aided diagnosis system, reading a CT image to be diagnosed and inputting the CT image into the system to obtain the probability that the CT image belongs to healthy liver, diffuse tumor, nodular tumor or giant-block tumor. The whole process of the method does not need the steps of image preprocessing and feature extraction, so that the process is simplified, and the final diagnosis accuracy is not influenced by image noise, low contrast and feature selection and extraction.
Rationale: Body mass index (BMI) is associated with chronic obstructive pulmonary disease (COPD) mortality, but the underlying mechanisms are unclear. The effect of genetic variants aggregated into a polygenic score may elucidate the causal mechanisms and predict risk. Objectives: To examine the associations of genetically predicted BMI with all-cause and cause-specific mortality in COPD. Methods: We developed a polygenic score (PGS) for BMI (PGSBMI) and tested for associations of the PGSBMI with all-cause, respiratory, and cardiovascular mortality in participants with COPD from the COPDGene (Genetic Epidemiology of COPD), ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points), and Framingham Heart studies. We calculated the difference between measured BMI and PGS-predicted BMI (BMIdiff) and categorized participants into groups of discordantly low (BMIdiff <20th percentile), concordant (BMIdiff between the 20th and 80th percentiles), and discordantly high (BMIdiff >80th percentile) BMI. We applied Cox models, examined potential nonlinear associations of the PGSBMI and BMIdiff with mortality, and summarized results with meta-analysis. Measurements and Main Results: We observed significant nonlinear associations of measured BMI and BMIdiff, but not PGSBMI, with all-cause mortality. In meta-analyses, a one-standard deviation increase in the PGSBMI was associated with an increased hazard for cardiovascular mortality (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.12-1.49), but not for respiratory or all-cause mortality. Compared with participants with concordant measured and genetically predicted BMI, those with discordantly low BMI had higher risks for all-cause mortality (HR, 1.57; 95% CI, 1.41-1.74) and respiratory death (HR, 2.01; 95% CI, 1.61-2.51). Conclusions: In people with COPD, a higher genetically predicted BMI is associated with higher cardiovascular mortality but not respiratory mortality. Individuals with a discordantly low BMI have higher all-cause and respiratory mortality rates than those with a concordant BMI.
PURPOSE: To evaluate the prevalence and characteristics of different HER2 categories among patients with advanced breast cancer (aBC) and describe treatment patterns and outcomes of those with HER2-low disease.
METHODS: A retrospective cohort study was conducted via chart review at the Huntsman Cancer Institute, including patients diagnosed with aBC (stages IIIB, IIIC and IV) between 2010 and 2019. All patients with IHC1+ were considered HER2-low unless FISH was positive. Patients with IHC2+ were only classified as HER2-low if a negative FISH was documented. The prevalence and characteristics of each HER2 category were reported. Treatment patterns and survival outcomes of HER2-low patients who received first line treatment in 2017 or later were presented.
RESULTS: A total of 240 of 414 patients (58%) with aBC were HER2-low, with the majority of patients (83%) classified as hormone receptor (HR)-positive. In first line, most HR-positive patients received endocrine therapy with chemotherapy for stage IIIB/IIIC (47%) and with CDK4/6 inhibitors for stage IV breast cancer (50%) Most HR-negative patients received chemotherapy alone (92% for stage IIIB/IIIC, 60% for stage IV). In second line, chemotherapy alone was the most common modality (21.4% for HR-positive; 45.5% for HR-negative). Median overall survival was 37.7 months while median progression-free survival from first line was 18.0 months, decreasing to 8.0 months in second line.
CONCLUSION: A substantial proportion of patients previously classified as HER2-negative have low but detectable HER2 expression and may benefit from novel HER2-directed agents, which have demonstrated clinical benefit in this population post-chemotherapy.
A system and method for predicting a lung cancer risk based on a chest X-ray in which a nodule is detected in a chest of a patient based on an analysis of the chest X-ray using an image processing technique. A region of interest associated with the nodule is identified using the image processing technique. The region of interest is further analyzed using deep learning to determine a plurality of characteristics associated with the nodule. The plurality of characteristics comprises a size of the nodule, a calcification in the nodule, a homogeneity of the nodule and a spiculation of the nodule. Further, the plurality of characteristics is compared with a trained data model using deep learning. Based on the comparison, a risk score associated with the nodule is generated. Further, the lung cancer risk is predicted when the risk score exceeds a predefined threshold value.
Sideline medical care is typically provided by musculoskeletal specialists and orthopaedic surgeons with varying levels of training and experience. While the most common sports injuries are often benign, the potential for catastrophic injury is omnipresent. Prompt recognition of sideline emergencies and expeditious medical management are necessary to minimize the risk of calamitous events. Paramount to successful sideline coverage are both preseason and game-day preparations. Because the skillset needed for the sideline physician may involve management of injuries not commonly seen in everyday clinical practice, sideline providers should review basic life support protocols, spine boarding, and equipment removal related to their sport(s) before the season begins. Before every game, the medical bag should be adequately stocked, location of the automatic external defibrillator/emergency medical services identified, and introductions to the trainers, coaches, and referees made. In addition to musculoskeletal injuries, the sideline orthopaedic surgeon must also be acquainted with the full spectrum of nonmusculoskeletal emergencies spanning the cardiopulmonary, central nervous, and integumentary systems. Familiarity with anaphylaxis as well as abdominal and neck trauma is also critical. Prompt identification of potential life-threatening conditions, carefully orchestrated treatment, and the athlete's subsequent disposition are essential for the team physician to provide quality care.